4 ms·

Can a kidney transplant drug keep you from aging?

22 points by melling 3y ago

jwilk 3y ago
https://archive.is/cTrvC https://archive.is/cTrvC
hkgjjgjfjfjfjf 3y ago
[dead]
m463 3y ago
https://en.wikipedia.org/wiki/Sirolimus https://en.wikipedia.org/wiki/Sirolimus seems like there may be a few side-effects...
- melling 3y ago
  The article mentions that but … “ side effects can be serious, and most doctors are wary of prescribing it off-label.” “6mg of the drug a week“ That’s a pretty low dosage?
  - robwwilliams 3y ago
    Yes, that dose is moderate and should have minimal adverse effects in most self-expermentalists. But we do not yet know much about possible adverse interactions between genetic variation and rapamycin effects—at least in terms of human subjects seeking better health and longer healthspans. We do not even have this type if data yet for mice (but stay tuned). On average rapamycin is highly effective in mice of both sexes and other species, but to the best of my knowledge there are no data yet on lifespan gains for primates like us.
robwwilliams 3y ago
This article just skims the surface. Here is more useful information: Rapamycin modulates activity of two related and key molecular complexes that have partly disjoint action. Health benefits and longevity are mainly associated with inhibition of the mTOR-C1 complex using a low or intermediate and often intermittent dose of rapamycin or other rapalogs (for example. see work of Dudley Lamming and Matt Kaeberlein in PubMed.) Inhibition of the mTOR-C2 requires somewhat higher rapamycin levels and may be required for transplant patients. But persistent mTOR-C2 inhibition is apparently the main cause of adverse outcomes. Most self-experimentation involve one or two oral doses in the range 0.2 to 0.6 mg every 5 to 10 days. This intermittent dosing will cause mTOR-C1 activity to oscillate in what users or their physicians hopes is a range without adverse immune suppression due to excessive drug action. Experimental work in mice indicates that initiation of treatment later in life is effective in health gains and lifespan, although not as effective as match treatment initiated earlier in adults. Short duration treatment of three months in mice (~5 years in human) is also somewhat effective, but again less so than longer term treatment. For graphs of survival curves of different treatments of genetically heterogeneous mice (by sex) see the impressive data of the Interventional Testing Program funded by NIH’s National Institute on Aging. https://phenome.jax.org/projects/ITP1 https://phenome.jax.org/projects/ITP1
irthomasthomas 3y ago
Discovered under the giant heads of Easter Island https://cen.acs.org/articles/94/i29/Rapamycins-Secrets-Unearthed.html https://cen.acs.org/articles/94/i29/Rapamycins-Secrets-Unear...

22 points by melling 3y ago

jwilk 3y ago

https://archive.is/cTrvC https://archive.is/cTrvC

hkgjjgjfjfjfjf 3y ago

[dead]

m463 3y ago

https://en.wikipedia.org/wiki/Sirolimus https://en.wikipedia.org/wiki/Sirolimus seems like there may be a few side-effects...

melling 3y ago
The article mentions that but … “ side effects can be serious, and most doctors are wary of prescribing it off-label.” “6mg of the drug a week“ That’s a pretty low dosage?
- robwwilliams 3y ago
  Yes, that dose is moderate and should have minimal adverse effects in most self-expermentalists. But we do not yet know much about possible adverse interactions between genetic variation and rapamycin effects—at least in terms of human subjects seeking better health and longer healthspans. We do not even have this type if data yet for mice (but stay tuned). On average rapamycin is highly effective in mice of both sexes and other species, but to the best of my knowledge there are no data yet on lifespan gains for primates like us.

robwwilliams 3y ago

This article just skims the surface. Here is more useful information: Rapamycin modulates activity of two related and key molecular complexes that have partly disjoint action. Health benefits and longevity are mainly associated with inhibition of the mTOR-C1 complex using a low or intermediate and often intermittent dose of rapamycin or other rapalogs (for example. see work of Dudley Lamming and Matt Kaeberlein in PubMed.) Inhibition of the mTOR-C2 requires somewhat higher rapamycin levels and may be required for transplant patients. But persistent mTOR-C2 inhibition is apparently the main cause of adverse outcomes. Most self-experimentation involve one or two oral doses in the range 0.2 to 0.6 mg every 5 to 10 days. This intermittent dosing will cause mTOR-C1 activity to oscillate in what users or their physicians hopes is a range without adverse immune suppression due to excessive drug action. Experimental work in mice indicates that initiation of treatment later in life is effective in health gains and lifespan, although not as effective as match treatment initiated earlier in adults. Short duration treatment of three months in mice (~5 years in human) is also somewhat effective, but again less so than longer term treatment. For graphs of survival curves of different treatments of genetically heterogeneous mice (by sex) see the impressive data of the Interventional Testing Program funded by NIH’s National Institute on Aging. https://phenome.jax.org/projects/ITP1 https://phenome.jax.org/projects/ITP1

irthomasthomas 3y ago

Discovered under the giant heads of Easter Island https://cen.acs.org/articles/94/i29/Rapamycins-Secrets-Unearthed.html https://cen.acs.org/articles/94/i29/Rapamycins-Secrets-Unear...